Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab add-on to brief educational intervention for migraine with medication overuse headache
2021-003049-40Phase 4Active
- Sponsor
- Lundbeck
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine and medication overuse headache (MOH) comparing Vyepti + brief educational intervention with Placebo + brief educational intervention (2 arms). Primary endpoint: Change from baseline in monthly migraine days. Started Apr 2022; status: active.
02
Drugs
eptinezumab
03
Conditions
migrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on 2021-003049-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003049-40.